Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
Rongce Zhao(Sun Yat-sen University), Rongping Guo(Sun Yat-sen University), Xinhao Xiong(Sun Yat-sen University), Zhaoxia Miao(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Shaohua Li(Sun Yat-sen University), Jing Zhou(Brigham and Women's Hospital)
Cited by 17
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
|European Journal of Endocrinology|2011|160